Use of delta5-androstene-3beta-ol-7, 17-dione in the treatment of lupus erythematosus
US6372732B1 · kind B1 · utility
3Cited by
4References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 4, 2000 |
| Grant date | Apr 16, 2002 |
| Priority date | — |
| Expiry date | Dec 4, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Lupus erythematosus can be treated by administering therapeutic amounts of delta-5-androstene-3-beta-ol-7,17-dione and its metabolizable precursors, which are not appreciably metabolized in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.